GRTX / Galera Therapeutics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 27, 2025 GALERA THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 27, 2025 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

Form of Second Amendment to Registration Rights Agreement

Exhibit 10.1 SECOND AMENDMENT TO REGISTRATION RIGHTS AGREEMENT This Second Amendment to the Registration Rights Agreement (this “Second Amendment”) is made and entered into as of June 5, 2025, by and among Galera Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

Form of Amendment to Pre-Funded Common Stock Purchase Warrant

Exhibit 10.3 AMENDMENT TO PRE-FUNDED COMMON STOCK PURCHASE WARRANT THIS AMENDMENT TO THE PRE-FUNDED COMMON STOCK PURCHASE WARRANT (this “Amendment”) is dated as of March 27, 2025, and is by and between Galera Therapeutics, Inc., a Delaware corporation (the “Company”), and [] (the “Holder”). RECITALS WHEREAS, the Company and the Holder are parties to that certain Pre-Funded Common Stock Purchase Wa

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2025 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza

Form of First Amendment to the Registration Rights Agreement

Exhibit 10.1 FIRST AMENDMENT TO REGISTRATION RIGHTS AGREEMENT This First Amendment to the Registration Rights Agreement (this “Amendment”) is made and entered into as of March , 2025 by and among Galera Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39114 Galera Therapeu

Consulting Agreement, dated January 1, 2025, by and between Galera Therapeutics, Inc. and Michael Friedman.

Exhibit 10.21 INDEPENDENT CONTRACTOR AGREEMENT THIS INDEPENDENT CONTRACTOR AGREEMENT (the “Agreement”) is made effective as of January 1, 2025 (the “Effective Date”) by and between Michael Friedman (“Contractor”), an individual with an address of 265 E. 66th Street, Apt. 4E, New York, NY 10065, and Galera Therapeutics, Inc., a Delaware corporation with an address of 101 Lindenwood Drive, Ste. 225,

Subsidiaries of Galera Therapeutics, Inc.

Exhibit 21.1 Subsidiaries of Galera Therapeutics, Inc. Legal Name of Subsidiary Jurisdiction of Organization Galera Labs, LLC Missouri, United States Nova Pharmaceuticals, Inc. Delaware, United States

Galera Therapeutics, Inc. Policy on Insider Trading

Exhibit 19.1 Galera Therapeutics, Inc. Insider Trading Compliance Policy (As of April 28, 2023) This Insider Trading Compliance Policy (this “Policy”) consists of seven sections: • Section I provides an overview; • Section II sets forth the policies of the Company prohibiting insider trading; • Section III explains insider trading; • Section IV consists of procedures that have been put in place by

Description of Securities

Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of securities of Galera Therapeutics, Inc. (the “Company,” “Galera,” “we,” “our,” or “us”) provides a summary of the rights of our capital stock as well as certain provisions of our Restated Certificate of Incorporation (our “Certific

Employment Agreement, dated April 1, 2019, by and between Galera Therapeutics, Inc. and Joel Sussman

Exhibit 10.20 Galera Therapeutics, Inc. Employment, Confidentiality, Noncompete and Invention Rights Agreement This Employment, Confidentiality, Noncompete and Invention Rights Agreement (“Agreement”) is made and entered into as of April 1, 2019 (the “Effective Date”) by and between Galera Therapeutics, Inc., a Delaware corporation (the “Company”), and Joel Sussman (“Employee”). Recitals A. Compan

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or org

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2025 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Certificate of Designation of Series B Non-Voting Series B Preferred Stock

Exhibit 3.1 CERTIFICATE OF DESIGNATION GALERA THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Galera Therapeutics, Inc., a Delaware corporation (the “Corporation”), that the followin

Agreement and Plan of Merger, dated as of December 30, 2024 by and among Galera, Grape Merger Sub I, Inc., Grape Merger Sub II, LLC and Nova(1)

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: GALERA THERAPEUTICS, INC., a Delaware corporation; GRAPE MERGER SUB I, INC., a Delaware corporation; GRAPE MERGER SUB II, LLC, a Delaware limited liability company; and NOVA PHARMACEUTICALS, INC., a Delaware corporation Dated as of December 30, 2024 TABLE OF CONTENTS Page SECTION 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Mer

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ

Securities Purchase Agreement, dated as of December 30, 2024, by and among Galera and each purchaser identified on Annex A thereto

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 30, 2024, by and among GALERA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each Purchaser is

Form of Registration Rights Agreement

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of December 30, 2024, by and among Galera Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securities

1

Exhibit 99.1 Galera Therapeutics completes acquisition of Nova Pharmaceuticals December 31, 2024 at 7:00 AM EST Galera’s development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is Phase 1/2 trial of Nova Pharmaceutical’s Clinical Stage Nitric Oxide Synthase (NOS) Inhibitor o

Forward-Looking Statements ©2025 Galera Therapeutics, Inc. Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from th

Galera Therapeutics (GRTX) Driving Better Outcomes for Breast Cancer Patients January 2025 Exhibit 99.

Form of Pre-Funded Warrant

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 20, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ

Separation Agreement and General Release, dated August 31, 2024, between the Company and Chris Degnan

Exhibit 10.1 GALERA THERAPEUTICS, INC. August 28, 2024 Chris Degnan Re: Separation Agreement Dear Chris: This letter sets forth the terms of the separation agreement (this “Agreement”) that Galera Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition from the Company. 1. Separation Date. You agree and acknowledge that your Company employment will terminate by w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REP

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from       to       Commission File Number: 001-39114 Galera Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one):  ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2024 ☐

SEC FILE NUMBER 001-39114 CUSIP NUMBER 36338D108 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 17, 2024 GALERA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 17, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 31, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

PRELIMINARY COPY – SUBJECT TO COMPLETION – DATED AUGUST 23, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursua

PRE 14A Table of Contents PRELIMINARY COPY – SUBJECT TO COMPLETION – DATED AUGUST 23, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2024 GALERA THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiz

Separation Agreement and General Release by Robert A. Beardsley, dated June 4, 2024

Exhibit 10.1 GALERA THERAPEUTICS, INC. June 4, 2024 Robert A. Beardsley, Ph.D. Re: Separation Agreement Dear Al: This letter sets forth the terms of the separation agreement (this “Agreement”) that Galera Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition from the Company. 1. Separation Date. You agree and acknowledge that your Company employment will termin

Galera Announces Board Approval of Complete Liquidation and Dissolution Company reports second quarter 2024 financial results

Exhibit 99.1 Galera Announces Board Approval of Complete Liquidation and Dissolution Company reports second quarter 2024 financial results MALVERN, Pa. – August 14, 2024 – Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2024 GALERA THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiz

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2024 GALERA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2024 GALERA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati

JOINT FILING AGREEMENT

EX-99.1 2 ea020627701ex99-1gale.htm JOINT FILING AGREEMENT CUSIP No. 36338D108 13G Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to certain shares of Common Stock of Galera Therapeut

GRTX / Galera Therapeutics, Inc. / Schneid Yair - AMENDMENT NO. 2 TO FORM SC 13G Passive Investment

SC 13G/A 1 ea0206277-13ga2schneidgale.htm AMENDMENT NO. 2 TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) GALERA THERAPEUTICS INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36338D108 (CUSIP Number) April 16, 2024 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT

GRTX / Galera Therapeutics, Inc. / Soffer Rochel - SCHEDULE 13G Passive Investment

SC 13G 1 ea0206277-13gsoffergale.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) GALERA THERAPEUTICS INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36338D108 (CUSIP Number) April 16, 2024 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate bo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2024 GALERA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates Company’s evaluation of potential strategic alternatives progresses with goal to maximize stockholder value

EX-99.1 Exhibit 99.1 Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates Company’s evaluation of potential strategic alternatives progresses with goal to maximize stockholder value MALVERN, Pa. – May 13, 2024 – Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that ha

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizatio

Stockholder Rights Agreement, dated as of May 3, 2024, by and between the Company and Equiniti Trust Company, LLC, as rights agent (which includes the Form of Rights Certificate as Exhibit B thereto)

Exhibit 4.1 STOCKHOLDER RIGHTS AGREEMENT Galera Therapeutics, Inc. and Equiniti Trust Company, LLC, as Rights Agent Dated as of May 3, 2024 Table of Contents Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 9 Section 3. Issuance of Rights Certificates 9 Section 4. Form of Rights Certificates 11 Section 5. Countersignature and Registration 12 Section 6. Transfer, Split U

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Galera Therapeutics, Inc. (Exact name of regi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Galera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1454898 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No

Certificate of Designation of the Series A Junior Participating Preferred Stock of the Company, dated May 3, 2024

Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF GALERA THERAPEUTICS, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned hereby certifies that the following resolution was duly adopted by the board of directors of Galera Therapeutics, Inc., a Delaware corporation (the “Corporation”), on May 2, 2024: RESOLVE

Galera Adopts Limited Duration Stockholder Rights Agreement

Exhibit 99.1 Galera Adopts Limited Duration Stockholder Rights Agreement MALVERN, Pa., May 3, 2024, Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the “Board”) has unanimously resolved to adopt a limited

GRTX / Galera Therapeutics, Inc. / Schneid Yair - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 ea0205114-13ga1schneidgale.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) GALERA THERAPEUTICS INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36338D108 (CUSIP Number) April 19, 2024 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMEN

GRTX / Galera Therapeutics, Inc. / ALPHA PHARMA Investments LLC - SCHEDULE 13G Passive Investment

Schedule 13G OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

GRTX / Galera Therapeutics, Inc. / Altamont Phamaceutical Holdings, Llc - AMENDMENT NO. 1 TO FORM SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galera Therapeutics, Inc. (GRTX) (Name of Issuer) Common Stock (Title of Class of Securities) 36338D108 (CUSIP Number) (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) April 1, 2024 (Date of Event which Requ

Galera Therapeutics, Inc. Policy for Recovery of Erroneously Awarded Compensation, effective as of October 2, 2023

Exhibit 97.1 GALERA THERAPEUTICS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Galera Therapeutics, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject t

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates Company continues to evaluate strategic options to maximize shareholder value

Exhibit 99.1 Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates Company continues to evaluate strategic options to maximize shareholder value MALVERN, Pa. – March 28, 2024 – Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiot

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza

Amended and Restated Bylaws of Galera Therapeutics, Inc.

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF GALERA THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39114 Galera Therapeu

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 21, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza

GRTX / Galera Therapeutics, Inc. / Sofinnova Venture Partners IX, L.P. - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 36338D108 (CUSIP Number) Nathalie Auber Sofinnova Investments,

GRTX / Galera Therapeutics, Inc. / SECTORAL ASSET MANAGEMENT INC - SC 13G/A Passive Investment

SC 13G/A 1 tm246006d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galera Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36338D108 (CUSIP Number) DECEMBER 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t

GRTX / Galera Therapeutics, Inc. / Schneid Yair - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) GALERA THERAPEUTICS INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36338D108 (CUSIP Number) January 5, 2024 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate box to designate the rule pursuant to which this Sc

GRTX / Galera Therapeutics, Inc. / GSA CAPITAL PARTNERS LLP Passive Investment

Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) : Galera Therapeutics ORD (Title of Class of Securities) : Common Stock (CUSIP Number) : 36338D108 (Date of Event Which Requires Filing of this Statement) : 31/12/2023 Check the appropriate box to designate the rule pursuant to which this Schedule is f

GRTX / Galera Therapeutics Inc / Blackstone Holdings I/II GP L.L.C. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 36338D108 (CUSIP Number) Robert Liptak Clarus Ventures, LLC 314 Main Street, 15th Floor Cambridge, MA 02142 (617) 949-2200 (Name,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder v

EX-99.1 Exhibit 99.1 Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa. – November 14, 2023 – Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focu

Separation Agreement and General Release by Mark Bachleda, dated August 16, 2023

Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE I, Mark Bachleda, in consideration of the obligations of Galera Therapeutics, Inc., a Delaware corporation (the “Company”), under that certain Employment, Confidentiality, Noncompete and Invention Rights Agreement (the “Agreement”), do hereby release and forever discharge, as of the date hereof, the Company and its affiliates and all present an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2023 GALERA THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ

GRTX / Galera Therapeutics Inc / Altamont Phamaceutical Holdings, Llc - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Galera Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36338D108 (CUSIP Number) October 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

Galera Announces Receipt of Type A Meeting Minutes and Strategic Update FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company re

EX-99.1 Exhibit 99.1 Galera Announces Receipt of Type A Meeting Minutes and Strategic Update FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential strategic alternatives to maximize shareholder value MALVERN, Pa., October 31, 2023– Galera Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2023 GALERA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 25, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or orga

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 22, 2023 GALERA THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 22, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or orga

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2023 GALERA THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps Cash runway extended in

EX-99.1 Exhibit 99.1 Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps Cash runway extended into Q2 2024 in connection with reduction in workforce FDA granted orphan drug designation to rucosopasem for the treatment of panc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2023 GALERA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza

Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps Galera will

EX-99.1 Exhibit 99.1 Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps Galera will take actions to extend its cash runway and continue enrolling its rucosopasem clinical trials Conference call tomorrow, August 10

GRTX / Galera Therapeutics Inc / Novo Holdings A/S - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 36338D108 (CUSIP Number) June 27, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2023 GALERA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 30, 2023 GALERA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 30, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati

As filed with the Securities and Exchange Commission on May 11, 2023

As filed with the Securities and Exchange Commission on May 11, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

Filing Fee Table

Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) Galera Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2023 Employment Inducem

Galera Reports First Quarter 2023 Financial Results and Recent Corporate Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023 Company raised $30 million in gross proceeds

EX-99.1 Exhibit 99.1 Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023 Company raised $30 million in gross proceeds from registered direct offering Company expanded commercial team and appointed leading biopharmaceutical executives with

Securities Purchase Agreement dated February 15, 2023 by and among Galera Therapeutics, Inc. and the purchasers named therein

Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 15, 2023, between Galera Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (including their successors and assigns, collectively, the “Purchasers” and each, a “Purchaser”). WHEREAS, subject to the terms and co

2023 Employment Inducement Award Plan and forms of award agreements thereunder

EXHIBIT 10.2 GALERA THERAPEUTICS, INC. 2023 EMPLOYMENT INDUCEMENT AWARD PLAN ARTICLE I. Purpose The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTIC

Form of Warrant to Purchase Common Stock, dated February 17, 2023, issued by Galera Therapeutics, Inc.

EXHIBIT 4.1 In accordance with Instruction 2 to Item 601 of Regulation S-K, below is a schedule setting forth details in which the omitted executed warrants differ from the form of warrant that follows: Warrantholder Warrant Number Number of Shares Armistice Capital Master Fund Ltd. 1 2,860,000 Alyeska Master Fund, LP 2 2,500,000 Deerfield Partners, L.P. 3 2,386,000 INVESTOR COMPANY ITF Rosalind M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2023 GALERA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati

Galera Therapeutics, Inc. Non-Employee Director Compensation Policy

Exhibit 10.1 Galera Therapeutics, Inc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the “Board”) of Galera Therapeutics, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or be made, as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 GALERA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39114 Galera Therapeu

Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023 Company raised $30 mi

EX-99.1 Exhibit 99.1 Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023 Company raised $30 million in gross proceeds from registered direct offering MALVERN, Pa. – March 8, 2023 – Galera Therapeutics, Inc. (Nasdaq: GRTX),

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2023 GALERA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizat

GRTX / Galera Therapeutics Inc / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

Form of Securities Purchase Agreement dated February 15, 2023 by and among the Company and the purchasers named therein

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 15, 2023, between Galera Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (including their successors and assigns, collectively, the “Purchasers” and each, a “Purchaser”). WHEREAS, subject to the terms and co

14,320,000 Shares of Common Stock Warrants to Purchase up to 14,320,000 Shares of Common Stock

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-251061 PROSPECTUS SUPPLEMENT (To Prospectus dated December 9, 2020) 14,320,000 Shares of Common Stock Warrants to Purchase up to 14,320,000 Shares of Common Stock We are offering 14,320,000 shares of common stock and warrants to purchase up to 14,320,000 shares of common stock. The common stock and warrants will be sold

Placement Agency Agreement dated February 15, 2023, by and between the Company and Piper Sandler & Co.

Exhibit 10.1 GALERA THERAPEUTICS, INC. PLACEMENT AGENCY AGREEMENT February 15, 2023 Piper Sandler & Co. 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Introductory. Galera Therapeutics, Inc., a Delaware corporation (the “Company”), hereby agrees to issue and sell up to an aggregate of $30,000,400 of registered securities of the Company, including (i) 14,320,000 shares (the “S

Form of Warrant

Exhibit 4.1 GALERA THERAPEUTICS, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Warrant No.: [ ⚫ ] Warrant Shares: Initial Exercise Date: February 17, 2023 THIS WARRANT TO PURCHASE COMMON STOCK (this “Warrant”) certifies that, for value received, [ ⚫ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2023 GALERA THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2023 GALERA THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ

GRTX / Galera Therapeutics, Inc. / SECTORAL ASSET MANAGEMENT INC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Original Filing)* Galera Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36338D108 (CUSIP Number) DECEMBER 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

GRTX / Galera Therapeutics, Inc. / Blackstone Holdings I/II GP L.L.C. - SC 13D Activist Investment

SC 13D 1 d452868dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 36338D108 (CUSIP Number) Robert Liptak Clarus Ventures, LLC 314 Main Street, 15th Floor Cambridge, MA 0214

JOINT FILING AGREEMENT

EX-99.A 2 d452868dex99a.htm EX-99.A Exhibit A JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”) the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder

GRTX / Galera Therapeutics, Inc. / Sofinnova Venture Partners IX, L.P. - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 36338D108 (CUSIP Number) Nathalie Auber Sofinnova Investments,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 24, 2023 GALERA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 24, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 12, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ

Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis NDA based on two positive randomized, double-blinded, placebo-controlled trials which enrolled a total of 678 patients

EX-99.1 Exhibit 99.1 Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis NDA based on two positive randomized, double-blinded, placebo-controlled trials which enrolled a total of 678 patients MALVERN, Pa. – December 12, 2022 – Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 6, 2022 GALERA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 6, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

Employment Agreement, dated October 7, 2021, by and between Galera Therapeutics, Inc. and Mark Bachleda and amendments to Employment Agreement, dated January 31, 2022 and September 19, 2022, by and between Galera Therapeutics, Inc. and Mark Bachleda

Exhibit 10.1 Galera Therapeutics, Inc. Employment, Confidentiality, Noncompete and Invention Rights Agreement This Employment, Confidentiality, Noncompete and Invention Rights Agreement (?Agreement?) is made and entered into as of October 7, 2021 by and between Galera Therapeutics, Inc., a Delaware corporation (the ?Company?), and Mark Bachleda (?Employee?). Recitals A. Effective as of the date Em

Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 One-year ROMAN follow-up data presented at 2022 American Society for Radiation Oncology (ASTRO)

EX-99.1 Exhibit 99.1 Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 One-year ROMAN follow-up data presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting showed tumor outcomes and overall survival maintained compared to placebo One-year ROMAN follow-up data also showe

Employment Agreement, dated July 25,2022, by and between Galera Therapeutics, Inc. and Eugene Kennedy

Exhibit 10.2 Galera Therapeutics, Inc. Employment, Confidentiality, Noncompete and Invention Rights Agreement This Employment, Confidentiality, Noncompete and Invention Rights Agreement (?Agreement?) is made and entered into as of July 25, 2022 by and between Galera Therapeutics, Inc., a Delaware corporation (the ?Company?), and Eugene Kennedy (?Employee?). Recitals A. Effective as of the date Emp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2022 GALERA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi

Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera’s o

EX-99.2 Exhibit 99.2 Transforming radiotherapy for patients with cancer October 2022 Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera’s own internal estimates and research. While Galera believes these t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2022 GALERA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi

Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting Tumor outcomes and overall survival maintained in patients with HNC at one-year Cisplatin-related chronic k

EX-99.1 Exhibit 99.1 Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting Tumor outcomes and overall survival maintained in patients with HNC at one-year Cisplatin-related chronic kidney disease reduced by 50% in avasopasem patients compared to placebo at one-year Meta-analysis of ROMAN and GT-201 (Phase 2b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Phase 3 ROMAN trial data highlighted in an oral presentation at the 2022 American Society of Cl

Exhibit 99.1 Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Phase 3 ROMAN trial data highlighted in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Phase 1 stage of GRECO-1 trial demonstrated rucosopasem in combination with SBRT was well tolerated

Galera Therapeutics, Inc. Non-Employee Director Compensation Program (effective as of February 11, 2021 and amended may 5, 2022)

Exhibit 10.1 Galera Therapeutics, Inc. Non-Employee Director Compensation Program (effective as of February 11, 2021 and amended may 5, 2022) Non-employee members of the board of directors (the ?Board?) of Galera Therapeutics, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compens

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizat

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 16, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 Data from its Ph

Exhibit 99.1 Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 Data from its Phase 3 ROMAN trial of avasopasem for SOM will be presented in an oral presentation at the upcoming 2022 American Society of Clinical Oncol

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza

Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates Positive Phase 3 ROMAN trial of avasopasem for severe oral mucositis met primary and secondary endpoint; Company intends to meet with FDA in 2022 about ND

EX-99.1 2 d310055dex991.htm EX-99.1 Exhibit 99.1 Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates Positive Phase 3 ROMAN trial of avasopasem for severe oral mucositis met primary and secondary endpoint; Company intends to meet with FDA in 2022 about NDA submission Data readouts from AESOP in esophagitis and GRECO-1 in lung cancer expected in 1H 2022 S

Employment Agreement, dated October 7, 2021, by and between Galera Therapeutics, Inc. and Mark Bachleda and amendment to Employment Agreement, dated January 31, 2022, by and between Galera Therapeutics, Inc. and Mark Bachleda

Exhibit 10.6 Galera Therapeutics, Inc. Employment, Confidentiality, Noncompete and Invention Rights Agreement This Employment, Confidentiality, Noncompete and Invention Rights Agreement (?Agreement?) is made and entered into as of October 7, 2021 by and between Galera Therapeutics, Inc., a Delaware corporation (the ?Company?), and Mark Bachleda (?Employee?). Recitals 1. Effective as of the date Em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39114 Galera Therapeu

GRTX / Galera Therapeutics, Inc. / CITADEL ADVISORS LLC - GALERA THERAPEUTICS, INC. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Galera Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (the ?Shares?) (Title of Class of Securities) 36338D108

JOINT FILING AGREEMENT

EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Galera Therapeutics, Inc.

GRTX / Galera Therapeutics, Inc. / Blackstone Holdings I/II GP L.L.C. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 36338D108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t

GRTX / Galera Therapeutics, Inc. / Rosalind Advisors, Inc. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Galera Therapeutics, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 36338D108 (CUSIP Number) February 4, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file

Joint Filing Agreement

EXHIBIT 99.3 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the shares of Common Stock, par value $0.001 per share, of Galera Therapeutics, Inc., a Delaware corporation, and further agree th

GRTX / Galera Therapeutics, Inc. / Novartis Bioventures Ltd - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

GRTX / Galera Therapeutics, Inc. / ADAGE CAPITAL PARTNERS GP, L.L.C. - GALERA THERAPEUTICS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 36338D108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs

GRTX / Galera Therapeutics, Inc. / Novo Holdings A/S - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36338D108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

JOINT FILING AGREEMENT

EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Galera Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the

GRTX / Galera Therapeutics, Inc. / CITADEL ADVISORS LLC - GALERA THERAPEUTICS, INC. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. )* Galera Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 36338D108 (CUSIP Number)

Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the

Exhibit 99.1 Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045) Topline results from single-arm Phase 2a trial of avasopasem in Europe

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ

Forward-Looking Statements @2021 Galera Therapeutics, Inc. Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from th

ROMAN Phase 3 Trial Update December 14, 2021 Exhibit 99.2 Forward-Looking Statements @2021 Galera Therapeutics, Inc. Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera?s own internal estimates and research. While Galera believes th

Employment Agreement, dated October 7, 2021, by and between Galera Therapeutics, Inc. and Mark Bachleda.

Exhibit 10.3 Galera Therapeutics, Inc. Employment, Confidentiality, Noncompete and Invention Rights Agreement This Employment, Confidentiality, Noncompete and Invention Rights Agreement (?Agreement?) is made and entered into as of October 7, 2021 by and between Galera Therapeutics, Inc., a Delaware corporation (the ?Company?), and Mark Bachleda (?Employee?). Recitals 1. Effective as of the date Em

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ

Employment Agreement, dated October 7, 2021, by and between Galera Therapeutics, Inc. and Jennifer Evans Stacey.

Exhibit 10.2 Galera Therapeutics, Inc. Employment, Confidentiality, Noncompete and Invention Rights Agreement This Employment, Confidentiality, Noncompete and Invention Rights Agreement (?Agreement?) is made and entered into as of October 7, 2021 by and between Galera Therapeutics, Inc., a Delaware corporation (the ?Company?), and Jennifer Evans Stacey (?Employee?). Recitals 1. Effective as of the

Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates Recently announced topline results of Phase 3 ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis Enrollment ongoing in GRECO-1 and GRECO-2 trials o

Exhibit 99.1 Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates Recently announced topline results of Phase 3 ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis Enrollment ongoing in GRECO-1 and GRECO-2 trials of rucosopasem (GC4711) in combination with SBRT in patients with NSCLC and Pancreatic Cancer; initial data from GRECO-1 expected in 1H202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

GRTX / Galera Therapeutics, Inc. / HIRSCHMAN ORIN Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 36338D108 (CUSIP Number) October 19, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 19, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi

Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis Primary endpoint of reduction in incidence of severe oral mucositis (SOM) not met Trial demonstrated relative reduction in all key SOM endpoi

Exhibit 99.1 Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis Primary endpoint of reduction in incidence of severe oral mucositis (SOM) not met Trial demonstrated relative reduction in all key SOM endpoints, including more than halving the median duration Avasopasem was generally well tolerated compared to placebo MALVERN, Pa., October 19

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2021 GALERA THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ

Forward-Looking Statements @2021 Galera Therapeutics, Inc. Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from th

Transforming radiotherapy for patients with cancer September 2021 Exhibit 99.1 Forward-Looking Statements @2021 Galera Therapeutics, Inc. Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera?s own internal estimates and research. Whi

Master Manufacturing Services Agreement between Patheon Manufacturing Services LLC and Galera Therapeutics, Inc., dated August 13, 2021

Exhibit 10.0 [***] = CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL and (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Master Manufacturing Services Agreement Effective Date: August 13, 2021 PARTIES PATHEON MANUFACTURING SERVICES LLC a limited liability company existing under the laws of the State of Delaware, USA, with a pla

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2021 GALERA THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiz

Galera Reports Second Quarter 2021 Financial Results and Recent Accomplishments Completed enrollment in pivotal Phase 3 ROMAN trial for severe oral mucositis (SOM) in patients with head and neck cancer; topline data expected in Q4 2021 Announced near

Exhibit 99.1 Galera Reports Second Quarter 2021 Financial Results and Recent Accomplishments Completed enrollment in pivotal Phase 3 ROMAN trial for severe oral mucositis (SOM) in patients with head and neck cancer; topline data expected in Q4 2021 Announced near doubling in median overall survival observed in interim analysis of 42-patient placebo-controlled pancreatic cancer trial; final results

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiz

Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizat

GRTX / Galera Therapeutics, Inc. / HIRSCHMAN ORIN - AMENDED SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 36338D108 (CUSIP Number) May 24, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

Galera Reports First Quarter 2021 Financial Results and Recent Accomplishments Phase 3 ROMAN trial in severe oral mucositis expected to complete enrollment in 1H21; topline data expected in 2H21 Recently announced near doubling of median overall surv

Exhibit 99.1 Galera Reports First Quarter 2021 Financial Results and Recent Accomplishments Phase 3 ROMAN trial in severe oral mucositis expected to complete enrollment in 1H21; topline data expected in 2H21 Recently announced near doubling of median overall survival observed in placebo-controlled pancreatic cancer trial Phase 2b pancreatic cancer trial, GRECO-2, expected to commence enrollment in

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 36338D108 (CUSIP Number) April 29, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

- DEF 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera’s o

Exhibit 99.1 Transforming radiotherapy for patients with cancer April 2021Exhibit 99.1 Transforming radiotherapy for patients with cancer April 2021 Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera?s ow

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 28, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39114 Galera Therapeu

Exhibit 4.2

Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2020, Galera Therapeutics, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). References herein to ?we,? ?us,? ?our? and the ?Company? refer to Galera Therape

Galera Therapeutics, Inc. Non-Employee Director Compensation Program (effective as of February 11, 2021)

Exhibit 10.10 Galera Therapeutics, Inc. Non-Employee Director Compensation Program (effective as of February 11, 2021) Non-employee members of the board of directors (the ?Board?) of Galera Therapeutics, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this

Galera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Accomplishments Pivotal Phase 3 ROMAN Trial in Severe Oral Mucositis on Track for Completion of Enrollment in 1H21; Topline Data Readout in 2H21 Anticipate Fin

Exhibit 99.1 Galera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Accomplishments Pivotal Phase 3 ROMAN Trial in Severe Oral Mucositis on Track for Completion of Enrollment in 1H21; Topline Data Readout in 2H21 Anticipate Final Data Readout from Locally Advanced Pancreatic Cancer (LAPC) Pilot Trial in 2H21 On Track for Initiation of Phase 2b GRECO-2 Trial of G

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securitie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 36338D108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of S

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 36338D108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to de

Galera Therapeutics, Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 36338D108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock (Title of class of securities) (CUSIP number) De

Amendment No. 2 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock (Title of class of securities) 36338D108 (CUSIP number) December 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designa

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Joint Filing Agreement

EXHIBIT 99.3 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the shares of Common Stock, par value $0.001 per share, of Galera Therapeutics, Inc., a Delaware corporation, and further agree th

Regulation FD Disclosure, Financial Statements and Exhibits

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or org

Disclaimers and Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party source

EX-99.1 Exhibit 99.1 Transforming Radiotherapy Transforming Radiotherapy with with Dismutase Mimetics Dismutase Mimetics January 2021Exhibit 99.1 Transforming Radiotherapy Transforming Radiotherapy with with Dismutase Mimetics Dismutase Mimetics January 2021 Disclaimers and Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presenta

-

GALERA THERAPEUTICS, INC. 2 W Liberty Blvd #100 Malvern, Pennsylvania 19355 December 7, 2020 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Mail Stop 3010 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Schwartz Re: GALERA THERAPEUTICS, INC. Registration Statement on Form S-3 (Registration No. 333-251061) Ladies and Gentlemen: In accordance

Open Market Sale AgreementSM, dated December 1, 2020, between the Company and Jefferies LLC.

EX-1.2 Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM December 1, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Galera Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company

Form of Indenture.

EX-4.6 Exhibit 4.6 GALERA THERAPEUTICS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page Article I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 Article II. THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establ

- S-3

S-3 Table of Contents As filed with the Securities and Exchange Commission on December 1, 2020 Registration No.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2020 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or o

Disclaimers and Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party source

EX-99.2 Transforming Radiotherapy with Dismutase Mimetics November 2020 Exhibit 99.2 Disclaimers and Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera’s own internal estimates and research. While Galera

Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates Presented Promising Interim Data from Placebo-controlled Pilot Dismutase Mimetic SBRT Combination Trial for Pancreatic Cancer Announced Planned Phase 2b GC

EX-99.1 2 d798681dex991.htm EX-99.1 Exhibit 99.1 Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates Presented Promising Interim Data from Placebo-controlled Pilot Dismutase Mimetic SBRT Combination Trial for Pancreatic Cancer Announced Planned Phase 2b GC4711 SBRT Combination Trial for Pancreatic Cancer (GRECO-2) Initiated Randomized Phase 1/2 GC4711 SBR

Quarterly Report - Q3 2020 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

GRTX / Galera Therapeutics, Inc. / Venrock Healthcare Capital Partners III, L.P. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 36338D108 (CUSIP Number) October 16, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs

Amended and Restated Bylaws of Galera Therapeutics, Inc.

EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF GALERA THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROC

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 24, 2020 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 16, 2020 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or

Disclaimers and Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party source

EX-99.1 Transforming Radiotherapy with Dismutase Mimetics September 2020 Exhibit 99.1 Disclaimers and Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera’s own internal estimates and research. While Galera

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 9, 2020 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or o

Disclaimers and Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party source

EX-99.1 Transforming Radiotherapy with Dismutase Mimetics September 2020 Exhibit 99.1 Disclaimers and Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera’s own internal estimates and research. While Galera

Warrant Purchase Agreement, dated May 11, 2020, by and between Galera Therapeutics, Inc. and Clarus IV Galera Royalty AIV, L.P.

Exhibit 10.2 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Execution Version WARRANT PURCHASE AGREEMENT This WARRANT PURCHASE AGREEMENT is dated as of May 11, 2020 (this “Agreement”) by and between Galera Therapeutics

Form of Warrant to Purchase Stock, dated May 11, 2020, issued by Galera Therapeutics, Inc. to Clarus IV Galera Royalty AIV, L.P., together with a schedule of warrantholders.

Exhibit 4.1 In accordance with Instruction 2 to Item 601 of Regulation S-K, below is a schedule setting forth details in which the omitted executed warrants differ from the form of warrant that follows: Warrantholder Number of Shares Milestone Clarus IV Galera Royalty AIV, L.P. 293,686 New Milestone Clarus IV Galera Royalty AIV, L.P. 256,975 Fourth Milestone Execution Version THIS WARRANT AND THE

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 d76779d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2020 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of

Galera Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates Completed Enrollment of Randomized, Blinded, Placebo-controlled Trial of GC4419 in Combination with Radiotherapy in Locally Advanced Pancreatic Cancer; To

EX-99.1 Exhibit 99.1 Galera Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates Completed Enrollment of Randomized, Blinded, Placebo-controlled Trial of GC4419 in Combination with Radiotherapy in Locally Advanced Pancreatic Cancer; Topline Data Readout Expected in 2H20 Phase 3 ROMAN Trial Remains on Track for Completion of Enrollment in 1H21 MALVERN, Pennsylvan

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

Amendment No. 1 to Amended and Restated Purchase and Sale Agreement, dated May 11, 2020, by and between Galera Therapeutics, Inc. and Clarus IV Galera Royalty AIV, L.P.

Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Execution Version GALERA THERAPEUTICS INC. AMENDMENT NO. 1 TO AMENDED AND RESTATED PURCHASE AND SALE AGREEMENT THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED PU

Disclaimers and Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party source

EX-99.1 Transforming Radiotherapy with Dismutase Mimetics July 2020 Exhibit 99.1 Disclaimers and Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera’s own internal estimates and research. While Galera beli

Regulation FD Disclosure, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 14, 2020 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or

Submission of Matters to a Vote of Security Holders

8-K 1 d940604d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2020 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction

Galera Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates ROMAN Phase 3 Trial Topline Data Readout Guidance Updated to 2H21 Due to Impact of COVID-19 Amendment to Royalty Agreement for Additional $37.5M Extends Ca

EX-99.1 Exhibit 99.1 Galera Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates ROMAN Phase 3 Trial Topline Data Readout Guidance Updated to 2H21 Due to Impact of COVID-19 Amendment to Royalty Agreement for Additional $37.5M Extends Cash Runway into 2H22 Locally Advanced Pancreatic Cancer Phase 1b/2a Trial Topline Data Readout and Initiation of NSCLC Anti-cancer

Disclaimers and Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party source

EX-99.2 Transforming Radiotherapy with Dismutase Mimetics May 2020 Exhibit 99.2 Disclaimers and Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera’s own internal estimates and research. While Galera belie

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2020 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or o

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2020 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

- DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Schedule 14A

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2020 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 d847406d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2020 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of

Galera Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments - Expanded Lead Product Candidate Avasopasem Manganese into Second Radiation Toxicity Indication - - Presented Data Demonstrating Avasopasem Ma

EX-99.1 Exhibit 99.1 Galera Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments - Expanded Lead Product Candidate Avasopasem Manganese into Second Radiation Toxicity Indication - - Presented Data Demonstrating Avasopasem Manganese Maintained Anti-Cancer Benefit of Chemoradiotherapy for Head and Neck Cancer While Substantially Reducing Radiation-Induc

Galera Therapeutics, Inc. Non-Employee Director Compensation Policy

Exhibit 10.11 Galera Therapeutics, Inc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the “Board”) of Galera Therapeutics, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), as amended and restated by the Board effective January 31, 2020. The cash and equity c

GRTX / Galera Therapeutics, Inc. 10-K - Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39114 Galera Therapeu

Description of Securities

EX-4.2 2 grtx-ex42236.htm EX-4.2 Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2019, Galera Therapeutics, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). References herein to “we,” “us,” “our” and the

GRTX / Galera Therapeutics, Inc. / Blackstone Holdings II L.P. - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 36338D108 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig

JOINT FILING AGREEMENT

Exhibit A Exhibit A JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”) the undersigned hereby agree to the joint filing of Clarus IV-A, L.

GRTX / Galera Therapeutics, Inc. / New Enterprise Associates 14, L.P. - NEW ENTERPRISE ASSOCIATES 14, L.P. - GALERA THERAPEUTICS, INC. -- SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 36338D108 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t

GRTX / Galera Therapeutics, Inc. / Novo A/S - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

Amendment No. 1 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock (Title of class of securities) 36338D108 (CUSIP number) December 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designa

GRTX / Galera Therapeutics, Inc. 10-Q - Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc.

Galera Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update - Completed Initial Public Offering of Common Stock That Raised Approximately $58 Million in Net Proceeds - - Progressed Pivotal Clinical Trial of GC4419 in

EX-99.1 Exhibit 99.1 Galera Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update - Completed Initial Public Offering of Common Stock That Raised Approximately $58 Million in Net Proceeds - - Progressed Pivotal Clinical Trial of GC4419 in Head & Neck Cancer with Topline Data Expected in 1H 2021 - MALVERN, Penn., December 10, 2019 – Galera Therapeutics, Inc. (Nasdaq

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 10, 2019 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or o

POWER OF ATTORNEY

EX-99.2 EXHIBIT 99.2 POWER OF ATTORNEY We, the undersigned, under the authority granted to each of us to sign jointly on behalf of Novartis AG, hereby grant powers to Bart Dzikowski, Anja Koenig, Stephan Sandmeier, Florian Muellershausen, Beat Steffen, Marc Ceulemans and Florent Gros and constitute and appoint any two of them jointly as our true and lawful attorneys and representatives and to act

GRTX / Galera Therapeutics, Inc. / Novartis Bioventures Ltd - SC 13G Passive Investment

SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.

Joint Filing Agreement

EX-99.3 EXHIBIT 99.3 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the shares of Common Stock, par value $0.001 per share, of Galera Therapeutics, Inc., a Delaware corporation, and further

EVIDENCE OF SIGNATURE AUTHORITY

EX-99.1 2 d837853dex991.htm EX-99.1 EXHIBIT 99.1 EVIDENCE OF SIGNATURE AUTHORITY Excerpt from Commercial Register of Novartis AG Identification number Legal status Entry Cancelled Carried CH-270.3.002.061-2-2 from: CH-270.3.002.061-2/a 1 CHE-103.867.266 Limited or Corporation 01.03.1996 on: All data In Ca Business name Ref Legal seat 1 Novartis AG 1 Basel 1 (Novartis SA) (Novartis Inc.) CHE-103.86

GRTX / Galera Therapeutics, Inc. / Sofinnova Venture Partners IX, L.P. - SC 13D Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 36338D108 (CUSIP Number) Nathalie Auber Sofinnova Investments,

GRTX / Galera Therapeutics, Inc. / Adage Capital Partners GP LLC Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 36338D108 (CUSIP Number) November 7, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant

GRTX / Galera Therapeutics, Inc. / Novo A/S - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Galera Therapeutics, Inc. (Name of Issuer) Common Stock (Title of class of securities) 36338D108 (CUSIP number) November 6, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whi

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2019 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation

Amended and Restated Bylaws of Galera Therapeutics, Inc.

EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF GALERA THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROC

Restated Certificate of Incorporation of Galera Therapeutics, Inc.

EX-3.1 Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF GALERA THERAPEUTICS, INC. The name of the corporation is Galera Therapeutics, Inc. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on November 19, 2012. This Restated Certificate of Incorporation of the corporation, which restates a

GRTX / Galera Therapeutics, Inc. S-8 - - FORM S-8

Form S-8 As filed with the Securities and Exchange Commission on November 8, 2019 Registration No.

5,000,000 Shares Common Stock

424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-234184 PROSPECTUS 5,000,000 Shares Common Stock This is Galera Therapeutics, Inc.’s initial public offering. We are selling 5,000,000 shares of our common stock. The public offering price is $12.00 per share. Prior to this offering, no public market existed for the shares. Our common stock has been approved for listing o

GRTX / Galera Therapeutics, Inc. CORRESP - -

CORRESP November 4, 2019 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Galera Therapeutics, Inc. Registration Statement on Form S-1 (as amended) (SEC File No. 333-234184) Ladies and Gentlemen: In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the req

GRTX / Galera Therapeutics, Inc. CORRESP - -

CORRESP November 4, 2019 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

Form 8-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Galera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1454898 (State of incorporation or organization) (I.R.S. Employer Identification No.) 2 W Liberty Blvd #

Galera Therapeutics, Inc. 2019 Employee Stock Purchase Plan

Exhibit 10.14 GALERA THERAPEUTICS, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purposes of this Galera Therapeutics, Inc. 2019 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the ?Plan?) are to assist Eligible Employees of Galera Therapeutics, Inc., a Delaware corporation (the ?Company?), and its Designated Subsidiaries in acquiring a stock owner

Employment Agreement, dated October 25, 2019, by and between Galera Therapeutics, Inc. and Robert A. Beardsley, Ph.D.

Exhibit 10.3 GALERA THERAPEUTICS, INC. EMPLOYMENT, CONFIDENTIALITY, NONCOMPETE AND INVENTION RIGHTS AGREEMENT This Employment, Confidentiality, Noncompete and Invention Rights Agreement (?Agreement?) is made and entered into as of October 25, 2019 by and between Galera Therapeutics, Inc., a Delaware corporation (the ?Company?), and Robert A. Beardsley, Ph.D. (?Employee?). RECITALS A. Company and E

Employment Agreement, dated October 25, 2019, by and between Galera Therapeutics, Inc. and Jon T. Holmlund, M.D.

Exhibit 10.5 GALERA THERAPEUTICS, INC. EMPLOYMENT, CONFIDENTIALITY, NONCOMPETE AND INVENTION RIGHTS AGREEMENT This Employment, Confidentiality, Noncompete and Invention Rights Agreement (?Agreement?) is made and entered into as of October 25, 2019 by and between Galera Therapeutics, Inc., a Delaware corporation (the ?Company?), and Jon T. Holmlund, M.D. (?Employee?). RECITALS A. Company and Employ

Form of Indemnification Agreement between Galera Therapeutics, Inc. and its directors and officers

Exhibit 10.7 GALERA THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the ?Agreement?) is made and entered into as of , 20[19] between Galera Therapeutics, Inc., a Delaware corporation (the ?Company?), and [Name] (?Indemnitee?). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors, officers or in other capacitie

Employment Agreement, dated October 25, 2019 by and between Galera Therapeutics, Inc. and Christopher Degnan

Exhibit 10.4 GALERA THERAPEUTICS, INC. EMPLOYMENT, CONFIDENTIALITY, NONCOMPETE AND INVENTION RIGHTS AGREEMENT This Employment, Confidentiality, Noncompete and Invention Rights Agreement (?Agreement?) is made and entered into as of October 25, 2019 by and between Galera Therapeutics, Inc., a Delaware corporation (the ?Company?), and Christopher Degnan (?Employee?). RECITALS A. Company and Employee